---
figid: PMC4231421__3141f7
figtitle: LPA-dependent platelet-induced tumor cell metastasis
organisms:
- Homo sapiens
- Mus musculus
pmcid: PMC4231421
filename: 3141f7.jpg
figlink: /pmc/articles/PMC4231421/figure/F7/
number: F7
caption: 'Schematic representation of LPA-dependent platelet-induced tumor cell metastasis.
  Tumor cell-induced platelet production of bioactive LPA (inhibitor: LPA receptor
  antagonist Ki16425) requires a first step of platelet aggregation that is prevented
  by selective inhibitors of αIIbβ3 integrin (RGDS, ReoPro), adenosine 5′-diphosphate
  activating pathway (Apyrase), and P2Y12 inhibitor (Clopidogrel). The second step
  requires the activation of phospholipases A1 and A2 (inhibitor: Palmostatin B) degrading
  membrane phospholipids among direct (phosphatidic acid) or indirect (phosphatidylcholine,
  phosphatidylserine, and phosphatidylethanolamine) precursors of LPA (LPC, lysophosphatidylserine,
  and lysophosphatidylethanolamine), that in turn are hydrolyzed by ATX/LysoPLD (ATX;
  lysoPLD inhibitors: BMP22 en PF-8380), released by activated platelets acting as
  free enzymes and/or bound to β3 integrins (αIIbβ3 and αVβ3). LPE, lysophosphatidylethanolamine;
  LPS, lysophosphatidyserine; PA, phosphatidic acid; PC, phosphatidylcholine; PE,
  phosphatidylethanolamine; PLA1, phospholipase A1; PLA2, phospholipase A2; PS, phosphatidylserine.'
papertitle: Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls
  metastasis of breast cancer cells to bone.
reftext: Raphael Leblanc, et al. Blood. 2014 Nov 13;124(20):3141-3150.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9296609
figid_alias: PMC4231421__F7
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC4231421__F7
ndex: 30953368-df0b-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4231421__3141f7.html
  '@type': Dataset
  description: 'Schematic representation of LPA-dependent platelet-induced tumor cell
    metastasis. Tumor cell-induced platelet production of bioactive LPA (inhibitor:
    LPA receptor antagonist Ki16425) requires a first step of platelet aggregation
    that is prevented by selective inhibitors of αIIbβ3 integrin (RGDS, ReoPro), adenosine
    5′-diphosphate activating pathway (Apyrase), and P2Y12 inhibitor (Clopidogrel).
    The second step requires the activation of phospholipases A1 and A2 (inhibitor:
    Palmostatin B) degrading membrane phospholipids among direct (phosphatidic acid)
    or indirect (phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine)
    precursors of LPA (LPC, lysophosphatidylserine, and lysophosphatidylethanolamine),
    that in turn are hydrolyzed by ATX/LysoPLD (ATX; lysoPLD inhibitors: BMP22 en
    PF-8380), released by activated platelets acting as free enzymes and/or bound
    to β3 integrins (αIIbβ3 and αVβ3). LPE, lysophosphatidylethanolamine; LPS, lysophosphatidyserine;
    PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine;
    PLA1, phospholipase A1; PLA2, phospholipase A2; PS, phosphatidylserine.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Vegfa
  - Egf
  - Ps
  - pc
  - bh
  - Pla2g2a
  - Pla2g5
  - Tlr4
  - Wdtc1
  - Mdga2
  - Enpp2
  - Dmbx1
  - P2ry12
  - Ralgds
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - EGF
  - PC
  - PCOLCE
  - POU2F3
  - PLA2G1B
  - PLA2G2A
  - PLA2G6
  - PLA2G3
  - PLA2G5
  - PLA2G7
  - PLA2G10
  - PLA2G12A
  - PLA2G12B
  - PLA2G2C
  - PLA2G2D
  - PLA2G2E
  - PLA2G2F
  - PLA2G4A
  - PLA2G4C
  - PLA2G4D
  - PCSK7
  - IRF6
  - WDTC1
  - ENPP2
  - SMG1
  - DMBX1
  - P2RY12
  - LPA
  - RALGDS
---
